Mate if PAA want to charge a premium for PPL-1, people will take the sheep drench.
Same will Albendazole.
The real money is in developing something novel. It is high risk but high reward. PAA is trying to cut corners. How many other pharma's are using this short cut methodology?
The Next Neuren, page-4
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
-0.010(4.88%) |
Mkt cap ! $94.85M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 21.0¢ | 19.0¢ | $186.0K | 934.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 115487 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 54290 | 2 |
View Market Depth
| Last trade - 13.32pm 30/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |